All In Biotech

Drug Trial Radar · NCT07676006

A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

May 2027

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Lead sponsor
Grit BiotechnologyIndustry
Sponsor type
Industry
Collaborators
Shenzhen People's Hospital
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, dose-escalation, prospective exploratory clinical study intended to evaluate the safety, efficacy and cellular pharmacokinetics of GT737 cells in adult patients with relapsed/refractory acute myeloid leukemia (AML).

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interventions

  • GT737 InjectionBiological

    GT737 Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants experiencing dose limiting toxicityTime frame: 28 days
  2. Adverse Events (AEs) occurring after infusion and their proportionsTime frame: 28 days
  3. Severity of Adverse Events (AEs) after infusionTime frame: 28 days
  4. Compare the differences in safety and tolerability between different treatment subgroups (monotherapy and combination with sirolimus).Time frame: 28 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.